AR020832A1 - Procedimiento para la preparacion de una composicion de alta pureza de (7alfa, 17alfa)-17-hidroxi-7-metil-19-nor-17-pregn-5-(10)-en-20-in-3-ona - Google Patents

Procedimiento para la preparacion de una composicion de alta pureza de (7alfa, 17alfa)-17-hidroxi-7-metil-19-nor-17-pregn-5-(10)-en-20-in-3-ona

Info

Publication number
AR020832A1
AR020832A1 ARP990105229A ARP990105229A AR020832A1 AR 020832 A1 AR020832 A1 AR 020832A1 AR P990105229 A ARP990105229 A AR P990105229A AR P990105229 A ARP990105229 A AR P990105229A AR 020832 A1 AR020832 A1 AR 020832A1
Authority
AR
Argentina
Prior art keywords
preparation
pregn
high purity
procedure
7alfa
Prior art date
Application number
ARP990105229A
Other languages
English (en)
Original Assignee
Organon Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8234220&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR020832(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Organon Nv filed Critical Organon Nv
Publication of AR020832A1 publication Critical patent/AR020832A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0081—Substituted in position 17 alfa and 17 beta
    • C07J1/0088—Substituted in position 17 alfa and 17 beta the substituent in position 17 alfa being an unsaturated hydrocarbon group
    • C07J1/0096—Alkynyl derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

Un procedimiento para la preparacion de una composicion de alta pureza de (7 alfa, 17 alfa)-17-hidroxi-7-metil-19-nor-17pregn-5(10)-en-20-in-3-ona. Elprocedimiento proporciona una composicion con menos de 0,5% de (7alfa; 17alfa)-17-hidroxi-7-metil-19 -nor-17-pregn-4-en-20-in-3-ona. Esta composicion puede serusada como una fuente para la preparacion de unidades de dosificacion farmacéuticas estables.
ARP990105229A 1998-10-16 1999-10-15 Procedimiento para la preparacion de una composicion de alta pureza de (7alfa, 17alfa)-17-hidroxi-7-metil-19-nor-17-pregn-5-(10)-en-20-in-3-ona AR020832A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP98203460 1998-10-16

Publications (1)

Publication Number Publication Date
AR020832A1 true AR020832A1 (es) 2002-05-29

Family

ID=8234220

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP990105229A AR020832A1 (es) 1998-10-16 1999-10-15 Procedimiento para la preparacion de una composicion de alta pureza de (7alfa, 17alfa)-17-hidroxi-7-metil-19-nor-17-pregn-5-(10)-en-20-in-3-ona

Country Status (30)

Country Link
US (3) US6969708B1 (es)
EP (2) EP1121375B1 (es)
JP (1) JP2002527525A (es)
KR (3) KR100635018B1 (es)
CN (2) CN100378116C (es)
AR (1) AR020832A1 (es)
AT (1) ATE239032T1 (es)
AU (1) AU763232B2 (es)
BR (1) BR9914441A (es)
CA (1) CA2344686C (es)
CO (1) CO5160271A1 (es)
CZ (1) CZ298703B6 (es)
DE (1) DE69907495T2 (es)
DK (1) DK1121375T3 (es)
ES (1) ES2197677T3 (es)
HK (1) HK1039620B (es)
HU (1) HUP0104206A3 (es)
ID (1) ID28463A (es)
IL (1) IL141850A (es)
NO (1) NO317427B1 (es)
NZ (1) NZ510501A (es)
PE (1) PE20001377A1 (es)
PL (1) PL197870B1 (es)
PT (1) PT1121375E (es)
RU (1) RU2220975C2 (es)
SK (1) SK284569B6 (es)
TR (2) TR200101083T2 (es)
TW (2) TW200403251A (es)
WO (1) WO2000023460A1 (es)
ZA (1) ZA200101952B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL356465A1 (en) * 2002-10-04 2004-04-05 ANPHARM Przedsiębiorstwo Farmaceutyczne S.A. METHOD OF MANUFACTURE OF 17beta-HYDROXY-7alpha-METHYL-19-NOR-17alpha-PREGN-5(10)-ENE-20-YNE-3-ONE
TW200418525A (en) * 2002-11-20 2004-10-01 Akzo Nobel Nv Coated pharmaceutical tablets containing Tibolone
GB0304927D0 (en) 2003-03-04 2003-04-09 Resolution Chemicals Ltd Process for the production of tibolone
WO2005117899A1 (en) * 2004-06-02 2005-12-15 Cipla Limited Pharmaceutical composition comprising tibolone and process for procuding the same
SI1848727T1 (sl) 2005-02-01 2015-09-30 F. Hoffmann-La Roche Ag Polimorf b ibandronata
WO2006081963A1 (en) * 2005-02-01 2006-08-10 F.Hoffmann-La Roche Ag Ibandronate polymorph a
EP1883648A1 (en) * 2005-05-23 2008-02-06 Newchem S.p.A. Process for the preparation of pure crystalline tibolone
CZ300465B6 (cs) * 2007-07-25 2009-05-27 Zentiva, A. S. Zpusob výroby komprimované farmaceutické formulace s obsahem tibolonu
ITMI20130120A1 (it) * 2013-01-25 2014-07-26 Ind Chimica Srl Processo per la preparazione in forma cristallina di tibolone, (7alfa,17alfa)-17-idrossi-7-metil-19-norpregn-5(10)-en-20-in-3-one
WO2020131917A1 (en) * 2018-12-17 2020-06-25 Aimmune Therapeutics, Inc. Formulations for egg oral immunotherapy, methods of manufacture, and treatments for egg allergy
CN114409717B (zh) * 2021-12-17 2023-03-17 湖南科益新生物医药有限公司 替勃龙中间体醚化物和替勃龙的制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE665514A (es) 1964-06-16
CH488682A (de) 1965-07-30 1970-04-15 Ciba Geigy Verfahren zur Herstellung von 4,9,11-Trienen der 19-Nor-androstanreihe
NL146838B (nl) 1966-06-24 1975-08-15 Organon Nv Werkwijze voor het bereiden van (delta)5(10)-3- keto-19-norsteroiden.
US3515719A (en) 1967-03-15 1970-06-02 Upjohn Co 7-methyl-6,19-epoxy steroids of the androstane series
US4701450A (en) * 1984-03-21 1987-10-20 Akzo N.V. Steroids for use as immunomodulators
JPH03503414A (ja) 1988-03-25 1991-08-01 アクゾ・エヌ・ヴエー フッ化物塩を含有する医薬製剤
IE63051B1 (en) * 1989-03-18 1995-03-22 Akzo Nv Pharmaceutical composition which contains a pharmaceutically suitable carrier and the compound having the structure (7alpha, 17alpha)-17-Hydroxy-7-methyl-19-nor-17-pregn-5(10)-en-20-yn- 3-one
EP0613687B1 (en) * 1993-03-05 1999-06-02 Akzo Nobel N.V. Use of a pregnane derivatives for the treatment of tumours
IL115445A (en) * 1994-10-17 1999-08-17 Akzo Nobel Nv Solid pharmaceutical compositions comprising low dosage active ingredient oil and excipient capable of binding water and their preparation
TW448049B (en) * 1997-03-05 2001-08-01 Akzo Nobel Nv Use of a 7Α-methyl-17Α-ethynyl-estrane derivative for the treatment of atherosclerosis
IL123984A (en) * 1997-04-22 2004-09-27 Akzo Nobel Nv Pharmacological dosage units containing tibolone and carrier pharmacy are acceptable

Also Published As

Publication number Publication date
KR100635018B1 (ko) 2006-10-17
SK284569B6 (sk) 2005-06-02
IL141850A0 (en) 2002-03-10
ZA200101952B (en) 2002-06-10
DK1121375T3 (da) 2003-08-04
US20040248870A1 (en) 2004-12-09
CZ2001976A3 (cs) 2001-08-15
TW577893B (en) 2004-03-01
HK1039620A1 (en) 2002-05-03
CA2344686C (en) 2009-04-28
PL197870B1 (pl) 2008-05-30
TW200403251A (en) 2004-03-01
JP2002527525A (ja) 2002-08-27
PL347264A1 (en) 2002-03-25
IL141850A (en) 2005-11-20
EP1121375A1 (en) 2001-08-08
US20050245496A1 (en) 2005-11-03
NO20011664D0 (no) 2001-04-03
SK4932001A3 (en) 2001-12-03
KR20010080133A (ko) 2001-08-22
CN1322210A (zh) 2001-11-14
BR9914441A (pt) 2001-06-26
ES2197677T3 (es) 2004-01-01
CN100432093C (zh) 2008-11-12
EP1275379A2 (en) 2003-01-15
NO20011664L (no) 2001-04-03
CN100378116C (zh) 2008-04-02
CN1769293A (zh) 2006-05-10
WO2000023460A1 (en) 2000-04-27
EP1121375B1 (en) 2003-05-02
CO5160271A1 (es) 2002-05-30
US6969708B1 (en) 2005-11-29
DE69907495T2 (de) 2004-05-06
AU763232B2 (en) 2003-07-17
EP1275379A3 (en) 2003-03-26
NO317427B1 (no) 2004-10-25
RU2220975C2 (ru) 2004-01-10
HUP0104206A3 (en) 2002-06-28
TR200504091T2 (tr) 2006-05-22
AU6202999A (en) 2000-05-08
CZ298703B6 (cs) 2007-12-27
HK1039620B (zh) 2003-08-22
NZ510501A (en) 2003-10-31
CA2344686A1 (en) 2000-04-27
KR20050003358A (ko) 2005-01-10
ATE239032T1 (de) 2003-05-15
PE20001377A1 (es) 2000-12-09
DE69907495D1 (de) 2003-06-05
HUP0104206A2 (hu) 2002-04-29
PT1121375E (pt) 2003-07-31
ID28463A (id) 2001-05-24
KR20060071897A (ko) 2006-06-27
TR200101083T2 (tr) 2001-08-21

Similar Documents

Publication Publication Date Title
SE9504661D0 (sv) New compounds
SE9704545D0 (sv) Novel compounds
BG105568A (en) Pharmaceutical compositions for modified release of an insulin sensitiser and another antidiabetic agent
MX9204268A (es) Una composicion para la liberacion prolongada y controlada de substancias medicamentosas y un proceso para preparar la misma.
EE02962B1 (et) Mometasoonfuroaadi monohüdraat, selle valmistamismeetod ja farmatseutilised kompositsioonid
DE69905170D1 (en) Thiazolopyrimidinderivate
SE9704546D0 (sv) Novel compounds
PT83933B (pt) Processo para a preparacao de composicoes estaveis de activador do plasminogenio humano, tipo tecido
AR020832A1 (es) Procedimiento para la preparacion de una composicion de alta pureza de (7alfa, 17alfa)-17-hidroxi-7-metil-19-nor-17-pregn-5-(10)-en-20-in-3-ona
IT1265101B1 (it) Derivati dell'acido 2-ammino-4-fenil-4-osso butirrico
ATE219061T1 (de) Huperzin a analoge verbindungen
TR200400228T4 (tr) Psöryazinin tedavisinde kullanılacak maddeler
PT1051159E (pt) Composicoes farmaceuticas solidas contendo miltefosina para administracao oral no tratamento de leishmaniose
AU4179399A (en) Use of nmda antagonists and/or sodium channel antagonists for the treatment of inflammatory disorders
AU623805B2 (en) New use of anti-progestomimetic compounds
NO983177L (no) Anvendelse av 1-enantiomeren av centkroman til fremstilling av et farmasaytisk preparat for behandling eller profylakse av brystkreft
ES2135722T3 (es) 1,5-benzodiacepinas 5-heterociclicas moduladoras de la cck o de la gastrina.
EA200100674A1 (ru) Клатраты дегидроэпиандростерона и соответствующие фармацевтические композиции
SE9504662D0 (sv) New compounds
NZ515685A (en) Use of riluzole for the treatment of multiple sclerosis
ES2177769T3 (es) Derivado de aminotetralina para la terapia de trastornos cardiovascu lares.
BR9906821A (pt) Composição farmacêutica e processo para melhorar a discinesia induzida por levodopa e discinesia tardia, e, uso de riluzol para a preparação de uma composição farmacêutica
ECSP993181A (es) Procedimiento para la preparacion de una composicion de alta pureza de (7alfa, 17alfa)- 17 - hidroxi-7-19-nor-17- pregn-5(10) -en -20-in-3-ona
BR9813037A (pt) Composto, processo para sua preparação, uso do mesmo, preparação farmacêutica, e, combinação desta com pelo menos uma outra substância ativa
GB0128071D0 (en) Medicament

Legal Events

Date Code Title Description
FB Suspension of granting procedure